Navigation Links
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
Date:9/4/2012

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at four investor conferences during the first two weeks of September. These four corporate presentations will be webcast.

Friday, September 7th at 8:30 a.m Eastern Time: NewsMakers in the Biotech Industry Conference in New York City

Monday, September 10th at 11:15 a.m. Eastern Time: Rodman & Renshaw Annual Global Investment Conference in New York City

Wednesday, September 12th at 10:55 a.m. Eastern Time: Morgan Stanley Global Healthcare Conference in New York City

Thursday, September 13th at 1:45 p.m. London Time: Bank of America Merrill Lynch Global Healthcare Conference in London

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after each event.

Additionally, on Wednesday, September 5th at 4:00 p.m. Eastern Time, Orexigen management will participate in a panel discussion at the Citi 7th Annual Biotech Day event. This event will not be webcast.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.  The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
2. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
3. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
4. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
5. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 RnRMarketResearch.com adds "Asthma - ... analysis of Asthma therapy at various stages, therapeutics assessment ... administration (RoA) and molecule type, along with latest updates, ... key players involved in the therapeutic development for Asthma ... Complete report on H1 2016 pipeline review of ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the rise ... and as an orthogonal tool for RNAi hit validation. A key reason may be ... RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh Report ... Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross ... “modern medical money maelstrom.” , During the interview with Mr. Feiner that aired ...
(Date:5/31/2016)... IL (PRWEB) , ... May 31, 2016 , ... ... multichannel marketing services firm and statement solutions provider, for the tenth ... in the May 2016 issue of Advertising Age, and SourceLink ranked eighteenth in ...
(Date:5/31/2016)... ... ... Super Powder, a supplement produced by Prox Formulas for providing protein ... to transform the nutritional supplement industry by providing a safe, natural approach to enhanced ... (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, B1, ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
Breaking Medicine News(10 mins):